Advertisement
Canada markets open in 1 hour 18 minutes
  • S&P/TSX

    22,813.75
    -58.90 (-0.26%)
     
  • S&P 500

    5,555.74
    -8.67 (-0.16%)
     
  • DOW

    40,358.09
    -57.35 (-0.14%)
     
  • CAD/USD

    0.7254
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    77.93
    +0.97 (+1.26%)
     
  • Bitcoin CAD

    91,565.61
    -339.38 (-0.37%)
     
  • CMC Crypto 200

    1,369.64
    +3.74 (+0.27%)
     
  • GOLD FUTURES

    2,418.70
    +11.40 (+0.47%)
     
  • RUSSELL 2000

    2,243.27
    +22.62 (+1.02%)
     
  • 10-Yr Bond

    4.2390
    -0.0210 (-0.49%)
     
  • NASDAQ futures

    19,704.50
    -220.50 (-1.11%)
     
  • VOLATILITY

    15.23
    +0.51 (+3.46%)
     
  • FTSE

    8,165.60
    -1.77 (-0.02%)
     
  • NIKKEI 225

    39,154.85
    -439.54 (-1.11%)
     
  • CAD/EUR

    0.6685
    +0.0003 (+0.04%)
     

Stocks in play: Marvel Biosciences Corp

Announces that along with its wholly owned subsidiary, Marvel Biotechnology Inc., it has completed the dosing portion of the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.10.

Read: